Characteristics of Study Population.

<p>HAART – highly active antiretroviral therapy; HBV/HHV-8 status obtained at time of blood draw; CNS – central nervous system; BL – Burkitt's lymphoma; NOS – not otherwise specified.</p

Complete List of Evaluated Biomarkers.

<p>Complete List of Evaluated Biomarkers.</p

Conditional Logistic Regression Analyses with Bonferroni Step-down Adjustment of Serum Biomarker Levels of AIDS-NHL and control subjects.

<p>SD – standard deviation, NS - non-significant;</p>†<p>concentration expressed as ng/ml, all others expressed in pg/ml; Biomarkers in bold represent consensus markers also selected by non-parametric statistics.</p

A-NHL biomarker pathway analysis.

<p>The Ingenuity Pathway Analysis (IPA) software package was utilized to identify pathways and specific interactions associated with the serum biomarkers identified in the current and previous reports. Biomarkers evaluated from the current study (rectangles) included CCL19, CXCL11, MCP-2, MIP-1δ, IFN-α, IL-11, IL-29, IP-10, M-CSF, sIL-1R1, C3, HPN, SAA, SAP, MMP-9, TIMP-1 and OC. Biomarkers evaluated based on previous findings (ovals) included IL-6, sCD30, IL-10, sCD23, sCD44, sCD27, CRP, BCA-1/CXCL13 and IgE. Solid lines indicate direct interactions, dashed lines indicate indirect interactions.</p

Spearman correlation between LILRB2 binding strength and odds ratios of <i>HLA</i> alleles (p<0.05) for viral load control in HIV-1-infected individuals.

<p>Spearman correlation between LILRB2 binding strength and odds ratios of <i>HLA</i> alleles (p<0.05) for viral load control in HIV-1-infected individuals.</p

Spearman correlation between LILRB2 binding strength and mVL in HIV-1-infected individuals.

<p>Spearman correlation between LILRB2 binding strength and mVL in HIV-1-infected individuals.</p

Effect of LILRB2-HLA binding strength and individual class I alleles on viral control (controllers vs. non-controllers) in white patients.

<p>Logistic regression model with stepwise selection included all <i>HLA</i> class I alleles with phenotypic frequencies of >2% and one of the A, B, C or ABC binding scores at a time. The results are shown for the p<0.05 cut-off. The C binding score did not stay in the model. ORs for binding scores reflect a change of 0.1 units.</p>1<p>stayed in the model with the p<0.01 cut-off but not with the p<0.001 cut-off.</p>2<p>stayed in the model with the p<0.01 and p<0.001 cut-offs.</p

LILRB2-HLA binding score variations in 2900 white (A) and 1490 black (B) patients.

<p>A, B and C binding scores represent the sum of the binding scores for two alleles of the corresponding <i>HLA</i> class I locus. ABC binding score represents the sum of the locus-specific binding scores with the C scores counted at 1/10 level. Alleles with undefined scores were assigned the average of the scores for a given locus. Box and Whisker plots reflect median, the 25% and 75% percentiles and the minimum and maximum of all data.</p

LILRB2 binding strength and odds ratios for viral load control for individual <i>HLA-B</i> alleles.

<p>The data plotted includes only alleles with significant association (p<0.05) for white (A) and black (B) patients in a univariate analysis for each <i>HLA-B</i> allele. Spearman correlation coefficient and p values are indicated.</p

Impact of LILRB2-HLA interactions on functional properties of dendritic cells.

<p>(A) Fold changes in proliferative activities of allogeneic CD4⁺ T cells after exposure to MDDC treated with indicated HLA-A, -B or -C allotypes normalized to MDDC treated with negative beads (N. Bead), in the absence (white bars, n = 5, 8, 5 for HLA-A, -B, -C allotypes, respectively) or presence (gray bars, n = 5, 6, 5 for HLA-A, -B, -C allotypes, respectively) of siRNA-mediated downregulation of LILRB2 surface expression on MDDC. Significance was tested using one-way ANOVA followed by post-hoc analysis with the Tukey multiple comparison test, or using paired t-tests, as appropriate, (^▪p<0.05, ^Xp<0.01, *p<0.001). (B): Spearman correlation between proliferative activities of allogeneic CD4⁺ T cells after incubation with MDDC treated with indicated HLA-A, -B and -C allotypes and corresponding LILRB2-HLA binding scores. (C): Spearman correlation between the ratios of MDDC function in the presence or absence of siRNA-mediated LILRB2 downregulation, and corresponding LILRB2-HLA-A, -B, -C binding scores.</p